Exponent, Inc. (NASDAQ:EXPO) has been given an average broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and two have issued a strong buy recommendation on the company. Exponent’s rating score has improved by 28.3% from 90 days ago as a result of various analysts’ ratings changes.
Analysts have set a one year consensus price objective of $83.00 for the company and are forecasting that the company will post $0.41 earnings per share for the current quarter, according to Zacks. Zacks has also given Exponent an industry rank of 156 out of 265 based on the ratings given to its competitors.
A number of brokerages have recently weighed in on EXPO. Cantor Fitzgerald restated a “buy” rating and set a $82.00 price target on shares of Exponent in a research note on Sunday, November 5th. SunTrust Banks restated a “hold” rating and set a $77.00 price target on shares of Exponent in a research note on Thursday, October 19th. BidaskClub lowered Exponent from a “hold” rating to a “sell” rating in a research note on Friday, December 15th. Finally, Zacks Investment Research lowered Exponent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 19th.
Shares of Exponent (NASDAQ:EXPO) traded up $0.35 during mid-day trading on Friday, hitting $76.00. The stock had a trading volume of 60,650 shares, compared to its average volume of 79,309. Exponent has a 1-year low of $55.75 and a 1-year high of $78.39. The stock has a market capitalization of $1,997.75, a price-to-earnings ratio of 37.07 and a beta of 0.57.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. purchased a new stake in Exponent in the fourth quarter valued at approximately $4,770,000. Conestoga Capital Advisors LLC boosted its position in Exponent by 13.8% in the fourth quarter. Conestoga Capital Advisors LLC now owns 973,140 shares of the business services provider’s stock valued at $69,190,000 after buying an additional 118,350 shares during the last quarter. GW&K Investment Management LLC boosted its position in Exponent by 17.9% in the fourth quarter. GW&K Investment Management LLC now owns 496,857 shares of the business services provider’s stock valued at $35,327,000 after buying an additional 75,277 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in Exponent by 8.5% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 149,465 shares of the business services provider’s stock valued at $10,627,000 after buying an additional 11,708 shares during the last quarter. Finally, California Public Employees Retirement System boosted its position in Exponent by 2.3% in the third quarter. California Public Employees Retirement System now owns 82,446 shares of the business services provider’s stock valued at $6,093,000 after buying an additional 1,846 shares during the last quarter. Hedge funds and other institutional investors own 89.29% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/14/brokerages-anticipate-exponent-inc-expo-to-announce-0-41-earnings-per-share.html.
Exponent, Inc (Exponent), along with its subsidiaries, is a science and engineering consulting company. Exponent provides engineering and scientific consulting services to clients around the world. Its service offerings are provided on a project-by-project basis. It operates in two segments: Engineering and Other Scientific, and Environmental and Health.
Get a free copy of the Zacks research report on Exponent (EXPO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Exponent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exponent and related companies with MarketBeat.com's FREE daily email newsletter.